{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:52:54Z","timestamp":1795027974571,"version":"4.10.2"},"reference-count":120,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for hematologic malignancies. However, it is frequently complicated by immune effector cell-associated hematotoxicity (ICAHT), a potentially life-threatening adverse event encompassing neutropenia, anemia, and thrombocytopenia. These cytopenias elevate the risk of severe infections, transfusion dependence, and prolonged hospital stays, contributing substantially to morbidity and non-relapse mortality. This review delineates the incidence, mechanisms, and risk factors for ICAHT, highlighting the complex interplay between disease burden, a patient\u2019s immune status, and features of the CAR T-cell products. Standardized grading systems, based on the depth and duration of neutropenia, have improved the classification of ICAHT and enabled more consistent risk stratification. Current prophylactic and therapeutic strategies, ranging from growth factor administration to hematopoietic stem cell boosts for refractory cases, are discussed, emphasizing tailored approaches to mitigate severe and prolonged hematotoxicity. These management strategies highlight the need for targeted interventions to prevent ICAHT without compromising the efficacy of the CAR T cells. As CAR T-cell therapy broadens to new indications, optimized ICAHT management could enhance patients\u2019 outcomes, reduce healthcare utilization, and increase therapy accessibility.<\/jats:p>","DOI":"10.3324\/haematol.2024.286027","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T03:14:27Z","timestamp":1740021267000},"page":"1254-1268","source":"Crossref","is-referenced-by-count":16,"title":["Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies"],"prefix":"10.3324","volume":"110","author":[{"given":"Ofrat","family":"Beyar-Katz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"75301","doi-asserted-by":"crossref","unstructured":"M\u00fcller F, Taubmann J, Bucci L. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024; 390(8):687-700.","DOI":"10.1056\/NEJMoa2308917"},{"key":"75302","doi-asserted-by":"crossref","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024; 21(7):501-521.","DOI":"10.1038\/s41571-024-00903-0"},{"key":"75303","doi-asserted-by":"crossref","unstructured":"Abramson JS, Palomba ML, Gordon LI. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"75304","doi-asserted-by":"crossref","unstructured":"Neelapu SS, Locke FL, Bartlett NL. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377(26):2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"75305","doi-asserted-by":"crossref","unstructured":"Schuster SJ, Bishop MR, Tam CS. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380(1):45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"75306","doi-asserted-by":"crossref","unstructured":"Shah BD, Ghobadi A, Oluwole OO. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021; 398(10299):491-502.","DOI":"10.1016\/S0140-6736(21)01222-8"},{"key":"75307","doi-asserted-by":"crossref","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021; 39(35):3978-3992.","DOI":"10.1200\/JCO.21.01992"},{"key":"75308","doi-asserted-by":"crossref","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022; 22(2):85-96.","DOI":"10.1038\/s41577-021-00547-6"},{"key":"75309","doi-asserted-by":"crossref","unstructured":"Hill JA, Li D, Hay KA. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018; 131(1):121-130.","DOI":"10.1182\/blood-2017-07-793760"},{"key":"75310","doi-asserted-by":"crossref","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024; 30(9):2667-2678.","DOI":"10.1038\/s41591-024-03084-6"},{"key":"75311","doi-asserted-by":"crossref","unstructured":"Tix T, Alhomoud M, Shouval R. Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients. Clin Cancer Res. 2024; 30(20):4690-4700.","DOI":"10.1158\/1078-0432.CCR-24-1798"},{"key":"75312","doi-asserted-by":"crossref","unstructured":"Storgard R, Rejeski K, Perales MA, Goldman A, Shouval R. T-cell malignant neoplasms after chimeric antigen receptor T-cell therapy. JAMA Oncol. 2024; 10(6):826-828.","DOI":"10.1001\/jamaoncol.2024.0662"},{"key":"75313","doi-asserted-by":"crossref","unstructured":"Rejeski K, Subklewe M, Aljurf M. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023; 142(10):865-877.","DOI":"10.1182\/blood.2023020578"},{"key":"75314","doi-asserted-by":"crossref","unstructured":"Rejeski K, Perez A, Iacoboni G. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL. J Immunother Cancer. 2022; 10(5):e004475.","DOI":"10.1136\/jitc-2021-004475"},{"key":"75315","doi-asserted-by":"crossref","unstructured":"Kampouri E, Little JS, Rejeski K, Manuel O, Hammond SP, Hill JA. Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies. Transpl Infect Dis. 2023; 25(Suppl 1):e14157.","DOI":"10.1111\/tid.14157"},{"key":"75316","doi-asserted-by":"crossref","unstructured":"Lemoine J, Bachy E, Cartron G. Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry. Blood Adv. 2023; 7(21):6589-6598.","DOI":"10.1182\/bloodadvances.2023010624"},{"key":"75317","doi-asserted-by":"crossref","unstructured":"Vic S, Thibert JB, Bachy E. Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study). Blood Adv. 2024; 8(6):1573-1585.","DOI":"10.1182\/bloodadvances.2023011727"},{"key":"75318","doi-asserted-by":"crossref","unstructured":"Lee DW, Santomasso BD, Locke FL. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25(4):625-638.","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"75319","doi-asserted-by":"crossref","unstructured":"Pennisi M, Jain T, Santomasso BD. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020; 4(4):676-686.","DOI":"10.1182\/bloodadvances.2019000952"},{"key":"75320","doi-asserted-by":"crossref","unstructured":"Rejeski K, Perez A, Sesques P. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/ refractory large B-cell lymphoma. Blood. 2021; 138(24):2499-2513.","DOI":"10.1182\/blood.2020010543"},{"key":"75321","doi-asserted-by":"crossref","unstructured":"Rejeski K, Hansen DK, Bansal R. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol. 2023; 16(1):88.","DOI":"10.1186\/s13045-023-01465-x"},{"key":"75322","doi-asserted-by":"crossref","unstructured":"Rejeski K, Wang Y, Albanyan O. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023; 98(11):1699-1710.","DOI":"10.1002\/ajh.27056"},{"key":"75323","doi-asserted-by":"crossref","unstructured":"Rejeski K, Greco R, Onida F. An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA. Hemasphere. 2023; 7(5):e889.","DOI":"10.1097\/HS9.0000000000000889"},{"key":"75324","doi-asserted-by":"crossref","unstructured":"Liang EC, Rejeski K, Fei T. Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity. Bone Marrow Transplant. 2024; 59(7):910-917.","DOI":"10.1038\/s41409-024-02278-3"},{"key":"75325","doi-asserted-by":"crossref","unstructured":"Rejeski K, Perez A, Iacoboni G. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023; 9(38):eadg3919.","DOI":"10.1126\/sciadv.adg3919"},{"key":"75326","doi-asserted-by":"crossref","unstructured":"Wudhikarn K, Palomba ML, Pennisi M. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J. 2020; 10(8):79.","DOI":"10.1038\/s41408-020-00346-7"},{"key":"75327","doi-asserted-by":"crossref","unstructured":"Rejeski K, Blumenberg V, Iacoboni G. Identifying early infections in the setting of CRS with routine and exploratory serum proteomics and the HT10 score following CD19 CAR-T for relapsed\/refractory B-NHL. Hemasphere. 2023; 7(4):e858.","DOI":"10.1097\/HS9.0000000000000858"},{"key":"75328","doi-asserted-by":"crossref","unstructured":"Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020; 136(8):925-935.","DOI":"10.1182\/blood.2019004000"},{"key":"75329","doi-asserted-by":"crossref","unstructured":"Little JS, Aleissa MM, Beluch K. Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Adv. 2022; 6(16):4821-4830.","DOI":"10.1182\/bloodadvances.2022007474"},{"key":"75330","doi-asserted-by":"crossref","unstructured":"Haidar G, Dorritie K, Farah R, Bogdanovich T, Nguyen MH, Samanta P. Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: a case series, review of the literature, and implications for prophylaxis. Clin Infect Dis. 2020; 71(3):672-676.","DOI":"10.1093\/cid\/ciz1127"},{"key":"75331","doi-asserted-by":"crossref","unstructured":"Rejeski K, Kunz WG, Rudelius M. Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report. BMC Infect Dis. 2021; 21(1):121.","DOI":"10.1186\/s12879-020-05755-4"},{"key":"75332","doi-asserted-by":"crossref","unstructured":"Cheok KPL, Farrow A, Springell D. Mucormycosis after CD19 chimeric antigen receptor T-cell therapy: results of a US Food and Drug Administration adverse events reporting system analysis and a review of the literature. Lancet Infect Dis. 2024; 24(4):e256-e265.","DOI":"10.1016\/S1473-3099(23)00563-7"},{"key":"75333","doi-asserted-by":"crossref","unstructured":"Rejeski K, Wang Y, Hansen DK. Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024; 8(8):1857-1868.","DOI":"10.1182\/bloodadvances.2023011767"},{"key":"75334","doi-asserted-by":"crossref","unstructured":"Elsallab M, Ellithi M, Lunning MA. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system. Blood. 2024; 143(20):2099-2105.","DOI":"10.1182\/blood.2024024166"},{"key":"75335","doi-asserted-by":"crossref","unstructured":"Alkhateeb HB, Mohty R, Greipp P. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma. Blood Cancer J. 2022; 12(7):113.","DOI":"10.1038\/s41408-022-00707-4"},{"key":"75336","doi-asserted-by":"crossref","unstructured":"Xia Y, Zhang J, Li J. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. Ann Med. 2022; 54(1):2951-2965.","DOI":"10.1080\/07853890.2022.2136748"},{"key":"75337","doi-asserted-by":"crossref","unstructured":"Fried S, Avigdor A, Bielorai B. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019; 54(10):1643-1650.","DOI":"10.1038\/s41409-019-0487-3"},{"key":"75338","doi-asserted-by":"crossref","unstructured":"Jain MD, Jacobs MT, Gao F. Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024; 8(4):1042-1050.","DOI":"10.1182\/bloodadvances.2023011489"},{"key":"75339","doi-asserted-by":"crossref","unstructured":"Roddie C, Neill L, Osborne W. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023; 7(12):2872-2883.","DOI":"10.1182\/bloodadvances.2022009019"},{"key":"75340","doi-asserted-by":"crossref","unstructured":"Teipel R, Kroschinsky F, Kramer M. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 2022; 6(6):1941-1946.","DOI":"10.1182\/bloodadvances.2021005747"},{"key":"75341","doi-asserted-by":"crossref","unstructured":"Miller PG, Sperling AS, Brea EJ. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021; 5(15):2982-2986.","DOI":"10.1182\/bloodadvances.2021004554"},{"key":"75342","doi-asserted-by":"crossref","unstructured":"Zhao Y, Bai X, Guo S. Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia. J Transl Med. 2024; 22(1):888.","DOI":"10.1186\/s12967-024-05705-7"},{"key":"75343","doi-asserted-by":"crossref","unstructured":"Del Bufalo F, De Angelis B, Caruana I. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023; 388(14):1284-1295.","DOI":"10.1056\/NEJMoa2210859"},{"key":"75344","doi-asserted-by":"crossref","unstructured":"Hegde M, Navai S, DeRenzo C. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024; 5(6):880-894.","DOI":"10.1038\/s43018-024-00749-6"},{"key":"75345","doi-asserted-by":"crossref","unstructured":"Saini NY, Swoboda DM, Greenbaum U. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov. 2022; 3(5):385-393.","DOI":"10.1158\/2643-3230.BCD-21-0177"},{"key":"75346","doi-asserted-by":"crossref","unstructured":"Hamilton MP, Sworder B, Alig S. CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias. Transplant Cell Ther. 2024; 30(2):S3-S4.","DOI":"10.1016\/j.jtct.2023.12.023"},{"key":"75347","doi-asserted-by":"crossref","unstructured":"Nair MS, Silbert SK, Rejeski K. Development of ALL-Hematotox (ALL-HT): predicting post CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia. 2025; 145(11):1136-1148.","DOI":"10.1182\/blood.2024025910"},{"key":"75348","doi-asserted-by":"crossref","unstructured":"Faramand RG, Lee SB, Jain MD. Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma. Blood Cancer Discov. 2024; 5(2):106-113.","DOI":"10.1158\/2643-3230.BCD-23-0056"},{"key":"75349","doi-asserted-by":"crossref","unstructured":"Raj S, Xie J, Fei T. An inflammatory biomarker signature reproducibly predicts CAR-T treatment failure in patients with aggressive lymphoma across the Zuma trials cohorts. Blood. 2023; 142(Supplement 1):224.","DOI":"10.1182\/blood-2023-173798"},{"key":"75350","doi-asserted-by":"crossref","unstructured":"Luft T, Benner A, Jodele S. EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematol. 2017; 4(9):e414-e423.","DOI":"10.1016\/S2352-3026(17)30108-4"},{"key":"75351","doi-asserted-by":"crossref","unstructured":"Greenbaum U, Strati P, Saliba RM. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021; 5(14):2799-2806.","DOI":"10.1182\/bloodadvances.2021004575"},{"key":"75352","doi-asserted-by":"crossref","unstructured":"Pennisi M, Sanchez-Escamilla M, Flynn JR. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021; 5(17):3397-3406.","DOI":"10.1182\/bloodadvances.2020003885"},{"key":"75353","doi-asserted-by":"crossref","unstructured":"Frenking JH, Zhou X, Wagner V. EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma. J Immunother Cancer. 2024; 12(10):e009220.","DOI":"10.1136\/jitc-2024-009220"},{"key":"75354","doi-asserted-by":"crossref","unstructured":"Bachy E, Le Gouill S, Di Blasi R. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 2022; 28(10):2145-2154.","DOI":"10.1038\/s41591-022-01969-y"},{"key":"75355","doi-asserted-by":"crossref","unstructured":"Luo W, Li C, Zhang Y. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and meta-analysis. BMC Cancer. 2022; 22(1):98.","DOI":"10.1186\/s12885-021-09102-x"},{"key":"75356","doi-asserted-by":"crossref","unstructured":"Kawalekar OU, RS OC, Fraietta JA. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016; 44(3):712.","DOI":"10.1016\/j.immuni.2016.02.023"},{"key":"75357","doi-asserted-by":"crossref","unstructured":"Zhao Z, Condomines M, van der Stegen SJC. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell. 2015; 28(4):415-428.","DOI":"10.1016\/j.ccell.2015.09.004"},{"key":"75358","doi-asserted-by":"crossref","unstructured":"Juluri KR, Wu QV, Voutsinas J. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2022; 6(7):2055-2068.","DOI":"10.1182\/bloodadvances.2020004142"},{"key":"75359","doi-asserted-by":"crossref","unstructured":"Jain T, Knezevic A, Pennisi M. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020; 4(15):3776-3787.","DOI":"10.1182\/bloodadvances.2020002509"},{"key":"75360","doi-asserted-by":"crossref","unstructured":"Wang Y, Song Z, Geng Y. The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy. Front Oncol. 2022; 12:987965.","DOI":"10.3389\/fonc.2022.987965"},{"key":"75361","doi-asserted-by":"crossref","unstructured":"Frigault MJ, Graham CE, Berger TR. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies. Blood. 2024; 144(11):1153-1167.","DOI":"10.1182\/blood.2024024104"},{"key":"75362","doi-asserted-by":"crossref","unstructured":"de Bruin AM, Demirel O, Hooibrink B, Brandts CH, Nolte MA. Interferon-gamma impairs proliferation of hematopoietic stem cells in mice. Blood. 2013; 121(18):3578-3585.","DOI":"10.1182\/blood-2012-05-432906"},{"key":"75363","doi-asserted-by":"crossref","unstructured":"Morales-Mantilla DE, King KY. The role of interferon-gamma in hematopoietic stem cell development, homeostasis, and disease. Curr Stem Cell Rep. 2018; 4(3):264-271.","DOI":"10.1007\/s40778-018-0139-3"},{"key":"75364","doi-asserted-by":"crossref","unstructured":"Giudice V, Feng X, Lin Z. Deep sequencing and flow cytometric characterization of expanded effector memory CD8(+)CD57(+) T cells frequently reveals T-cell receptor Vbeta oligoclonality and CDR3 homology in acquired aplastic anemia. Haematologica. 2018; 103(5):759-769.","DOI":"10.3324\/haematol.2017.176701"},{"key":"75365","doi-asserted-by":"crossref","unstructured":"Rejeski K, Wu Z, Blumenberg V. Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL. Blood. 2022; 140(20):2175-2179.","DOI":"10.1182\/blood.2022017015"},{"key":"75366","doi-asserted-by":"crossref","unstructured":"Strati P, Li X, Deng Q. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNgamma-expressing CD8 T cells. Cell Rep Med. 2023; 4(8):101158.","DOI":"10.1016\/j.xcrm.2023.101158"},{"key":"75367","doi-asserted-by":"crossref","unstructured":"Penack O, Peczynski C, Koenecke C. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. J Immunother Cancer. 2023; 11(4):e006406.","DOI":"10.1136\/jitc-2022-006406"},{"key":"75368","doi-asserted-by":"crossref","unstructured":"Zhou J, Zhang Y, Shan M. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma. Front Immunol. 2022; 13:997589.","DOI":"10.3389\/fimmu.2022.997589"},{"key":"75369","doi-asserted-by":"crossref","unstructured":"Wudhikarn K, Pennisi M, Garcia-Recio M. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020; 4(13):3024-3033.","DOI":"10.1182\/bloodadvances.2020001972"},{"key":"75370","doi-asserted-by":"crossref","unstructured":"Logue JM, Peres LC, Hashmi H. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022; 6(24):6109-6119.","DOI":"10.1182\/bloodadvances.2022008320"},{"key":"75371","doi-asserted-by":"crossref","unstructured":"Brudno JN, Natrakul D, Lam N, Dulau-Florea A, Yuan CM, Kochenderfer JN. Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. Leuk Lymphoma. 2022; 63(8):1849-1860.","DOI":"10.1080\/10428194.2022.2056172"},{"key":"75372","doi-asserted-by":"crossref","unstructured":"Pascutti MF, Erkelens MN, Nolte MA. Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on bone marrow output. Front Immunol. 2016; 7:364.","DOI":"10.3389\/fimmu.2016.00364"},{"key":"75373","doi-asserted-by":"crossref","unstructured":"Sandler RD, Tattersall RS, Schoemans H. Diagnosis and management of secondary HLH\/MAS following HSCT and CAR-T cell therapy in adults; a review of the Literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol. 2020; 11:524.","DOI":"10.3389\/fimmu.2020.00524"},{"key":"75374","doi-asserted-by":"crossref","unstructured":"Hines MR, Knight TE, McNerney KO. Immune effector cell-associated hemophagocytic lymphohistiocytosis-Like syndrome. Transplant Cell Then. 2023; 29(7):438.e1-438.e16.","DOI":"10.1016\/j.jtct.2023.03.006"},{"key":"75375","doi-asserted-by":"crossref","unstructured":"Porter TJ, Lazarevic A, Ziggas JE. Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel. Br J Haematol. 2022; 199(5):720-727.","DOI":"10.1111\/bjh.18454"},{"key":"75376","doi-asserted-by":"crossref","unstructured":"Rejeski K, Jain MD, Shah NN, Perales MA, Subklewe M. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. Lancet Haematol. 2024; 11(6):e459-e470.","DOI":"10.1016\/S2352-3026(24)00077-2"},{"key":"75377","doi-asserted-by":"crossref","unstructured":"Bhagwat AS, Torres L, Shestova O. Cytokine-mediated CAR T therapy resistance in AML. Nat Med. 2024; 30(12):3697-3708.","DOI":"10.1038\/s41591-024-03271-5"},{"key":"75378","doi-asserted-by":"crossref","unstructured":"Ghilardi G, Paruzzo L, Patel V. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel. J Hematol Oncol. 2024; 17(1):19.","DOI":"10.1186\/s13045-024-01542-9"},{"key":"75379","doi-asserted-by":"crossref","unstructured":"Ghilardi G, Paruzzo L, Svoboda J. Bendamustine Lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines. Blood Adv. 2024; 8(3):653-666.","DOI":"10.1182\/bloodadvances.2023011492"},{"key":"75380","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Wulf GG, Duell J. Hematopoietic stem cell boost for persistent neutropenia after CAR T-ceLL therapy: a GLA\/DRST study. Blood Adv. 2023; 7(4):555-559.","DOI":"10.1182\/bloodadvances.2022008042"},{"key":"75381","doi-asserted-by":"crossref","unstructured":"Ahmed N, Shahzad M, Shippey E. Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transplant Cell Then. 2022; 28(7):358.","DOI":"10.1016\/j.jtct.2022.04.008"},{"key":"75382","doi-asserted-by":"crossref","unstructured":"Battram AM, Oliver-Caldes A, Suarez-Lledo M. T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells. Mol Ther Methods Clin Dev. 2022; 26:207-223.","DOI":"10.1016\/j.omtm.2022.06.010"},{"key":"75383","doi-asserted-by":"crossref","unstructured":"Shahid Z, Jain T, Dioverti V. Best practice considerations by the American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies. Transplant Cell Ther. 2024; 30(10):955-969.","DOI":"10.1016\/j.jtct.2024.07.018"},{"key":"75384","doi-asserted-by":"crossref","unstructured":"Maung ZT, Wood AC, Jackson GH, Turner GE, Appleton AL, Hamilton PJ. Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic Lymphocytic Leukaemia. Br J Haematol. 1994; 88(3):649-652.","DOI":"10.1111\/j.1365-2141.1994.tb05093.x"},{"key":"75385","doi-asserted-by":"crossref","unstructured":"Bindal P, Elavalakanar P, Trottier CA. G-CSF administration is associated with worse treatment response and survival after CAR T-cell therapy. Blood. 2022; 140(Supplement 1):5238-5240.","DOI":"10.1182\/blood-2022-167976"},{"key":"75386","doi-asserted-by":"crossref","unstructured":"Gaut D, Tang K, Sim MS, Duong T, Young P, Sasine J. Filgrastim associations with CAR T-cell therapy. Int J Cancer. 2021; 148(5):1192-1196.","DOI":"10.1002\/ijc.33356"},{"key":"75387","doi-asserted-by":"crossref","unstructured":"Miller KC, Johnson PC, Abramson JS. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J. 2022; 12(10):146.","DOI":"10.1038\/s41408-022-00741-2"},{"key":"75388","doi-asserted-by":"crossref","unstructured":"Ma S, Li H, Zhou D. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Cytotherapy. 2023; 25(6):653-658.","DOI":"10.1016\/j.jcyt.2023.01.011"},{"key":"75389","doi-asserted-by":"crossref","unstructured":"Li Y, Guo R, Wang L, Li S, Zhu Z, Tu P. G-CSF administration results in thrombocytopenia by inhibiting the differentiation of hematopoietic progenitors into megakaryocytes. Biochem Pharmacol. 2019; 169:113624.","DOI":"10.1016\/j.bcp.2019.113624"},{"key":"75390","doi-asserted-by":"crossref","unstructured":"Shimba A, Ikuta K. Control of immunity by glucocorticoids in health and disease. Semin Immunopathol. 2020; 42(6):669-680.","DOI":"10.1007\/s00281-020-00827-8"},{"key":"75391","doi-asserted-by":"crossref","unstructured":"Wang J, Zhang M, Lyu H. Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy. Front Immunol. 2023; 14:1139559.","DOI":"10.3389\/fimmu.2023.1139559"},{"key":"75392","doi-asserted-by":"crossref","unstructured":"Nagle SJ, Murphree C, Raess PW. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies. Am J Hematol. 2021; 96(4):455-461.","DOI":"10.1002\/ajh.26113"},{"key":"75393","doi-asserted-by":"crossref","unstructured":"Beyar-Katz O, Perry C, On YB. Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells-single-center experience. Ann Hematol. 2022; 101(8):1769-1776.","DOI":"10.1007\/s00277-022-04889-6"},{"key":"75394","doi-asserted-by":"crossref","unstructured":"Drillet G, Lhomme F, De Guibert S, Manson G, Houot R. Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists. Blood Adv. 2023; 7(4):537-540.","DOI":"10.1182\/bloodadvances.2022008066"},{"key":"75395","doi-asserted-by":"crossref","unstructured":"Wesson W, Ahmed N, Rashid A. Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias. Eur J Haematol. 2024; 112(4):538-546.","DOI":"10.1111\/ejh.14141"},{"key":"75396","doi-asserted-by":"crossref","unstructured":"Beyar Katz O, Perry C, Grisariu-Greenzaid S. Response rates of extra-nodal diffuse large B cell lymphoma to anti- CD19-CAR T cells: a real word retrospective multicenter study. Eur J Haematol. 2023; 111(1):63-71.","DOI":"10.1111\/ejh.13968"},{"key":"75397","doi-asserted-by":"crossref","unstructured":"Mingot-Castellano ME, Reguera-Ortega JL, Zafra Torres D. Use of eltrombopag to improve thrombocytopenia and tranfusion requirement in anti-CD19 CAR-T cell-treated patients. J Clin Med. 2024; 13(17):5117.","DOI":"10.3390\/jcm13175117"},{"key":"75398","doi-asserted-by":"crossref","unstructured":"Mullanfiroze K, Lazareva A, Chu J. CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy. Blood Adv. 2022; 6(16):4715-4718.","DOI":"10.1182\/bloodadvances.2022007572"},{"key":"75399","doi-asserted-by":"crossref","unstructured":"Rejeski K, Burchert A, Iacoboni G. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Adv. 2022; 6(16):4719-4725.","DOI":"10.1182\/bloodadvances.2022007776"},{"key":"75400","doi-asserted-by":"crossref","unstructured":"Crombie JL, Graff T, Falchi L. Consensus recommendations on the management of toxicity associated with CD3xCD20 bispecific antibody therapy. Blood. 2024; 143(16):1565-1575.","DOI":"10.1182\/blood.2023022432"},{"key":"75401","doi-asserted-by":"crossref","unstructured":"de Assis LH, Fassi DE, Hutchings M. Bispecific antibody therapies. Hematology Am Soc Hematol Educ Program. 2023; 2023(1):216-222.","DOI":"10.1182\/hematology.2023000508"},{"key":"75402","doi-asserted-by":"crossref","unstructured":"Budde LE, Sehn LH, Matasar M. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022; 23(8):1055-1065.","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"75403","doi-asserted-by":"crossref","unstructured":"Thieblemont C, Phillips T, Ghesquieres H. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial. J Clin Oncol. 2023; 41(12):2238-2247.","DOI":"10.1200\/JCO.22.01725"},{"key":"75404","doi-asserted-by":"crossref","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022; 387(24):2220-2231.","DOI":"10.1056\/NEJMoa2206913"},{"key":"75405","doi-asserted-by":"crossref","unstructured":"Hutchings M, Morschhauser F, Iacoboni G. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021; 39(18):1959-1970.","DOI":"10.1200\/JCO.20.03175"},{"key":"75406","doi-asserted-by":"crossref","unstructured":"Chari A, Minnema MC, Berdeja JG. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022; 387(24):2232-2244.","DOI":"10.1056\/NEJMoa2204591"},{"key":"75407","doi-asserted-by":"crossref","unstructured":"D\u2019Souza A, Shah N, Rodriguez C. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2022; 40(31):3576-3586.","DOI":"10.1200\/JCO.22.01504"},{"key":"75408","doi-asserted-by":"crossref","unstructured":"Moreau P, Garfall AL, van de Donk N. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022; 387(6):495-505.","DOI":"10.1056\/NEJMoa2203478"},{"key":"75409","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Garfall AL, van de Donk N. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021; 398(10301):665-674.","DOI":"10.1016\/S0140-6736(21)01338-6"},{"key":"75410","doi-asserted-by":"crossref","unstructured":"Lievin R, Di Blasi R, Morin F. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma. Bone Marrow Transplant. 2022; 57(3):431-439.","DOI":"10.1038\/s41409-021-01526-0"},{"key":"75411","doi-asserted-by":"crossref","unstructured":"Galli E, Allain V, Di Blasi R. G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory\/relapsed B-cell lymphoma. Bone Marrow Transplant. 2020; 55(12):2347-2349.","DOI":"10.1038\/s41409-020-01006-x"},{"key":"75412","doi-asserted-by":"crossref","unstructured":"Barreto JN, Bansal R, Hathcock MA. The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy. Am J Hematol. 2021; 96(10):E399-E402.","DOI":"10.1002\/ajh.26313"},{"key":"75413","doi-asserted-by":"crossref","unstructured":"Sureda A, Kr\u00f6ger N, Apperley J, Gratwohl A. The EBMT: history, present, and future. 2024.","DOI":"10.1007\/978-3-031-44080-9_2"},{"key":"75414","doi-asserted-by":"crossref","unstructured":"Carson JL, Stanworth SJ, Guyatt G. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023; 330(19):1892-1902.","DOI":"10.1001\/jama.2023.12914"},{"key":"75415","doi-asserted-by":"crossref","unstructured":"Schiffer CA, Bohlke K, Delaney M. Platelet transfusion for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018; 36(3):283-299.","DOI":"10.1200\/JCO.2017.76.1734"},{"key":"75416","doi-asserted-by":"crossref","unstructured":"Davis JA, Sborov DW, Wesson W. Efficacy and safety of CD34+ stem cell boost for delayed hematopoietic recovery after BCMA directed CAR T-cell therapy. Transplant Cell Ther. 2023; 29(9):567-571.","DOI":"10.1016\/j.jtct.2023.05.012"},{"key":"75417","doi-asserted-by":"crossref","unstructured":"Mohan M, Szabo A, Patwari A. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone Marrow Transplant. 2024; 59(5):647-652.","DOI":"10.1038\/s41409-024-02233-2"},{"key":"75418","doi-asserted-by":"crossref","unstructured":"Baur R, Jitschin R, Kharboutli S. Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report. J Immunother Cancer. 2021; 9(7):e002721.","DOI":"10.1136\/jitc-2021-002721"},{"key":"75419","doi-asserted-by":"crossref","unstructured":"Laham Y, Ringelstein-Harlev S, Kurnik D. High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies. Haematologica. 2025.","DOI":"10.3324\/haematol.2024.286714"},{"key":"75420","doi-asserted-by":"crossref","unstructured":"Xing L, Wang Y, Liu H. Case report: sirolimus alleviates persistent cytopenia after CD19 CAR-T-cell therapy. Front Oncol. 2021; 11:798352.","DOI":"10.3389\/fonc.2021.798352"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11947\/78082","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11947\/78409","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11947\/78082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:13Z","timestamp":1794046093000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":120,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286027","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,20]]}}}